POZEN Receives FDA CRL Following Active Ingredient Supplier Facility Inspection

Last week, POZEN announced that the company had received a complete response letter for its drug candidates PA8140/PA32540 (aspirin and omeprazole) delayed release tablets after the FDA after an inspection of one of POZEN’s manufacturing facilities.
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news